Uy Ear
Stock Analyst at Mizuho
(4.21)
# 455
Out of 5,140 analysts
77
Total ratings
48.94%
Success rate
19.78%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $135.41 | +29.24% | 11 | Dec 12, 2025 | |
| QURE uniQure | Maintains: Outperform | $60 → $33 | $21.74 | +51.79% | 6 | Dec 9, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $4.90 | +287.76% | 4 | Dec 2, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $24 → $29 | $26.76 | +8.37% | 15 | Dec 2, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $32 → $37 | $26.70 | +38.58% | 15 | Nov 28, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $1 → $10 | $3.81 | +162.47% | 2 | Nov 19, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $19 → $26 | $21.37 | +21.67% | 9 | Nov 5, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $33.85 | +32.94% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $41.09 | +36.29% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $18.81 | +352.01% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $7.64 | +423.56% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $218.01 | -81.65% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.34 | +327.35% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.49 | +101.34% | 2 | Mar 1, 2023 |
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $135.41
Upside: +29.24%
uniQure
Dec 9, 2025
Maintains: Outperform
Price Target: $60 → $33
Current: $21.74
Upside: +51.79%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $4.90
Upside: +287.76%
ACADIA Pharmaceuticals
Dec 2, 2025
Maintains: Neutral
Price Target: $24 → $29
Current: $26.76
Upside: +8.37%
Arcutis Biotherapeutics
Nov 28, 2025
Maintains: Outperform
Price Target: $32 → $37
Current: $26.70
Upside: +38.58%
Relmada Therapeutics
Nov 19, 2025
Upgrades: Outperform
Price Target: $1 → $10
Current: $3.81
Upside: +162.47%
Sarepta Therapeutics
Nov 5, 2025
Upgrades: Outperform
Price Target: $19 → $26
Current: $21.37
Upside: +21.67%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $33.85
Upside: +32.94%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $41.09
Upside: +36.29%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $18.81
Upside: +352.01%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $7.64
Upside: +423.56%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $218.01
Upside: -81.65%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.34
Upside: +327.35%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.49
Upside: +101.34%